Alnylam Pharmaceuticals Inc (ALNY)vsZevra Therapeutics Inc. (ZVRA)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
ZVRA
Zevra Therapeutics Inc.
$9.13
-0.22%
HEALTHCARE · Cap: $537.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3388% more annual revenue ($3.71B vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs 8.5%. ZVRA trades at a lower P/E of 6.8x. ZVRA earns a higher WallStSmart Score of 62/100 (C+).
ALNY
Hold49
out of 100
Grade: D+
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Margin of Safety
+7.6%
Fair Value
$9.18
Current Price
$9.13
$0.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Strong operational efficiency at 27.3%
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
1.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : ZVRA
The primary concerns for ZVRA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a hypergrowth stock while ZVRA is a value play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.94 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (62/100 vs 49/100), backed by strong 78.2% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?